Biotech Stocks Reviews
- Essa Eyeing Big Pharma Combination Partner For N-Terminal Domain Candidate
Wed, Sep 23
The $45M financing last August has given Essa enough funding (~$80M cash) to now pursue combination · more » - Tau’s Big First Test in Alzheimer’s Disease Flops
Wed, Sep 23
AC Immune (ACIU) reported that semorinemab, their Phase 2 anti-tau candidate partnered with Genentech, · more » - Expectations for Upcoming AC Immune & Genentech Semorinemab Data
Sun, Sep 13
AC Immune announced a $80M ATM with Jeffries yesterday. With $280M in cash, good to last for at least 24 · more » - Trillium’s Early Monotherapy Lymphoma Data Demonstrates Best-In-Class Potential
Wed, Sep 9
Trillium (TRIL), a name many readers have expressed interest in, announced two material pieces of news · more » - Merck’s Phase 3 in Chronic Cough Lowers Expectations for P2X3
Tue, Sep 8
Merck announced data for their Phase 3 cough program this morning and it was rather disappointing. · more » - Market Miscalculating Chance of Success for Aerpio’s Phase 2
Thu, Aug 20
Aerpio (ARPO) is developing a novel treatment for glaucoma that has Phase 2 data by the end of 2020. · more » - Affimed Earns Milestone Payment as Roche Gets BCMA Candidate Into Clinic
Tue, Aug 11
Affimed (AFMD) announced Q2 results today, which showed that the pipeline is progressing as planned. · more » - Manufacturing Issue Leads to Fennec CRL
Tue, Aug 11
Fennec announced that the FDA issued a CRL for Pedmark, citing manufacturing issues. The FDA did not · more » - Giapreza Sales Underwhelm As It Doesn’t See A COVID Pickup
Thu, Aug 6
Today La Jolla (LJPC) announced Q2 results for Giapreza and numbers were very underwhelming. For the · more »